In a court hearing Tuesday in the U.S. District Court for the Northern District of California, Holmes’ attorneys said Adam Rosendorf, former director of the Theranos Institute, who was one of the government’s key witnesses, was accused on August 8. Arrived at her house and asked to speak with her.
According to the filing, Rosendorf did not interact with Holmes, but did speak with her partner, Billy Evans.
Evans said of Rosendorf, “His shirt was untied, his hair was unkempt, and his voice was slightly quivering.” I tried to answer, but the prosecutor said he tried to make everyone look bad.”
The former director of the Theranos lab also “said he felt like he did something wrong,” Evans wrote.
In testifying over six days last October, Rosendorff said he left the company with “extreme skepticism” about the accuracy and reliability of the company’s tests. He testified that he felt that it was “a matter of my integrity as a doctor” to continue to stand by test results that he “did not trust” beyond the company. has come to believe that PR and fundraising are more important than patient care.”
Rosendorf and the federal prosecutor in the case against Holmes did not immediately respond to requests for comment.
In Tuesday’s filing, Holmes’ attorney said the conversation between Rosendorf and Evans constitutes new evidence to justify a new trial.
“Dr. Rosendorf’s statement reflects his concerns about the government’s submission of his trial testimony, and along with his comments relating to Ms. I am seriously skeptical,” they wrote. “The court should allow a new trial or at least order a hearing of evidence.”
Their trial marked the final chapter for Theranos, a startup once valued at $9 billion and hailed for its promise to upend the healthcare industry. Theranos claimed its technology could accurately and efficiently test for conditions such as cancer and diabetes with just a few drops of blood. That commitment has attracted $945 million in funding, a panel of prominent politicians, and prominent retail partners.
A subsequent journal investigation into the company cast doubt on the company’s testing methods and the capabilities of its technology. In 2018, Holmes and Balwani were each charged with numerous wire fraud and conspiracy to commit wire fraud.
Both have pleaded not guilty and are due for sentencing later this year, with Holmes’ sentencing hearing scheduled for mid-October and Balwani’s sentencing hearing scheduled for mid-November.